Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

+44 1300 500008

Ghaid Touza

Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA

  • Research Article   
    A Meta-Analysis and Systematic Review of Mavacamten a Novel Disease-Specific Treatment for Hypertrophic Obstructive Cardiomyopathy
    Author(s): Ziad Affas*, Ghaid Touza, Rowaid Touza, Saif Affas, Zain Azzo and Ali Shakir

    Background: Hypertrophic cardiomyopathy (HCM) is a common genetically based cardiac disease with an estimated prevalence of 1 in 200-500 cases that poses a significant threat to young adults and athletes. The genetic basis of HCM involves sequence variations in several genes that encode proteins of the thick and thin cardiac myofilaments which are responsible for the contraction of the cardiac sarcomere. Pathogenic mutations that cause hypertrophic cardiomyopathy are transmitted in an autosomal dominant pattern. HCM is generally stratified into obstructive (about 70%) and non-obstructive hypertrophic cardiomyopathy. Clinical manifestation of HCM can range from asymptomatic to drug-refractory advanced heart failure. Mavacamten is a first-in-class myosin inhibiting drug that has progressed through in vitro studies. It has shown promising results in patients wit.. View More»
    DOI: 10.35248/2155-9880.22.13.722

    Abstract HTML PDF